FIGURE 1.
Theranostic radiohybrid concept applied to PSMA-targeted ligands. Molecules offer 2 labeling sites for radionuclides, silicon-fluorine acceptor site for 18F labeling via isotopic exchange and chelator for radiometallation. 18F-labeled cold lutetium–complexed ligand ([18F]Lu-rhPSMA) is chemically identical to 177Lu-labeled cold fluorine compound ([177Lu]Lu-rhPSMA), therefore representing true theranostic agents for PET imaging and RLT.